The goal of this prospective study is to learn whether there is a synergistic effect when radiotherapy is combined with ripretinib in the treatment of patients with unresectable advanced GIST. It will also learn about the safety of this regimen.The main questions it aim to answer is: Dose radiotherapy combined with ripretinib prolong the time to disease progression for patients with advanced GIST?
Voluntary participation and signed informed consent;
age: 18 to 75 years, Male or female
Patients with histologically confirmed GIST and Imaging evaluated as unresectable recurrent and metastatic disease or locally advanced.
ECOG Performance Score: 0-2
estimated life-expectancy less than 3 months.
Patients who have received previous radiotherapy to the proposed radiotherapy site, or the tumor has significant mobility, poor tolerance of radiotherapy in adjacent organs, and who are considered unsuitable for radiotherapy after MDT discussion
Any other clinically significant comorbidities, which in the judgment of the investigator, could compromise compliance with the protocol, interfere with interpretation of the study results, or predispose the patient to safety risks.
If female, the patient is pregnant or lactating, or plans to become pregnant during the study treatment period
First Affiliated Hospital of Chongqing Medical University
Lead sponsor
Peking University Cancer Hospital & Institute
Collaborator